<DOC>
	<DOCNO>NCT02286921</DOCNO>
	<brief_summary>Asymptomatic men progressive metastatic CRPC post- treatment abiraterone acetate ( pre-chemotherapy metastatic disease ) treat randomize , multi-Institutional open label study determine treatment intramuscular T give dose/schedule design result rapid cycling polar extreme supraphysiologic near castrate level [ i.e . Bipolar Androgen Therapy ( BAT ) ] improve primary secondary objective vs. enzalutamide standard therapy .</brief_summary>
	<brief_title>Testosterone Revival Abolishes Negative Symptoms , Fosters Objective Response Modulates Enzalutamide Resistance</brief_title>
	<detailed_description>Eligible patient metastatic CRPC disease relate symptom progression ADT progress post-treatment abiraterone . Patients continue ADT LHRH agonist ( i.e . Zoladex , Trelstar , Eligard Lupron ) LHRH antagonist ( Degarelix ) surgically castrate throughout duration study inhibit endogenous testosterone production . Patients randomize 1:1 stratified base duration prior abiraterone acetate therapy ( 6 month less great 6 month ) . Patients randomized BAT ( Arm A ) receive intramuscular injection either testosterone cypionate testosterone enanthate dose 400 mg every 28 day . This dose select base data demonstrate produce initial supraphysiologic serum level T ( i.e . &gt; 1500 ng/dL 3-10 time normal level ) eugonadal level achieve end two week near castrate level 28 day . Patients randomized enzalutamide ( Arm B ) receive daily oral dose 160 mg. Each cycle define 28 day . Patients PSA level symptom assessment check every cycle . Every 3 cycle patient repeat bone/CT scan evaluate treatment response status . On CT scan , radiographic progression define RECIST criterion ( i.e . &gt; 20 % increase sum target lesion ) . On bone scan , radiographic progression define PCWG2 criterion ≥ 2 new bone lesion . However , first reassessment scan , patient remain study confirmatory scan perform 12 week ( 3 cycle ) later . If confirmatory scan show 2 additional new lesion , defines progression . The date progression date first reassessment bone scan . If confirmatory scan show additional new lesion , patient remain study . If progression observe subsequent bone scan , confirmatory scan require ; date bone scan date progression . Patients PSA progression disease response stable disease image study remain study radiographic clinical progression criterion meet . Patients radiographic disease progression receive continue BAT ( arm A ) enzalutamide ( arm B ) eligible crossover opposite therapy . Patients BAT arm A cross receive enzalutamide time progression choose go study treat standard care treatment . Patients enzalutamide arm B allow cross-over receive BAT choose go study treat standard care treatment . Patients clinical progression due prostate cancer must meet study exclusion criterion permit cross-over opposite treatment . Patients clinical progression due pain prostate cancer permit cross-over .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>1 . ECOG Performance status ≤2 2 . Age ≥18 year 3 . Histologicallyconfirmed adenocarcinoma prostate 4 . Treated continuous androgen ablative therapy ( either surgical castration LHRH agonist/antagonist ) 5 . Documented castrate level serum testosterone ( &lt; 50 ng/dl ) 6 . Metastatic disease radiographically document CT/MRI bone scan . 7 . Must disease progression abiraterone acetate alone abiraterone acetate combination investigational agent base : PSA progression define increase PSA , determine 2 separate measurement take least 1 week apart And/Or Radiographic disease progression , base RECIST 1.1 patient measurable soft tissue lesion , PCWG2 patient bone disease 8 . Screening PSA must ≥ 1.0 ng/mL . 9 . Prior treatment additional second line hormone therapy allow . 10 . No prior treatment enzalutamide , ARN509 , ODM201 , galeterone investigational AR target treatment allow . 11 . Prior docetaxel hormonesensitive prostate cancer permit ≤ 6 dos give conjunction firstline androgen deprivation therapy &gt; 12 month since last dose docetaxel . 12 . Prior treatment Provenge vaccine 223Radium ( Xofigo ) allow &gt; 4 week last dose . 13 . Patients must withdraw abiraterone ≥ 2 week . 14 . Patients must wean prednisone therapy ≥ 1 week prior start therapy . 15 . Acceptable liver function : 1 . Bilirubin &lt; 2.5 time institutional upper limit normal ( ULN ) 2 . AST ( SGOT ) ALT ( SGPT ) &lt; 2.5 time ULN 16 . Acceptable renal function : a. Serum creatinine &lt; 2.5 time ULN 17 . Acceptable hematologic status : 1 . Absolute neutrophil count ( ANC ) ≥ 1500 cells/mm3 ( 1.5 ×109/L ) 2 . Platelet count ≥ 100,000 platelet/mm3 ( 100 ×109/L ) 3 . Hemoglobin ≥ 9 g/dL . 18 . At least 4 wks since prior radiation . 19 . Ability understand willingness sign write informed consent document . 20 . Patients either treatment arm consider crossover demonstrate evidence radiographic disease progression . 1 . Pain due metastatic prostate cancer require treatment intervention . 2 . ECOG Performance status ≥3 3 . Prior treatment enzalutamide prohibit 4 . Prior treatment docetaxel cabazitaxel metastatic castrationresistant prostate cancer prohibit . 5 . Requires urinary catheterization void due obstruction secondary prostatic enlargement well document due prostate cancer benign prostatic hyperplasia ( BPH ) . 6 . Evidence disease sit extent , opinion investigator , would put patient risk therapy testosterone ( e.g . femoral metastasis concern fracture risk , severe extensive spinal metastasis concern spinal cord compression , extensive liver metastasis ) 7 . Evidence serious and/or unstable preexist medical , psychiatric condition ( include laboratory abnormality ) could interfere patient safety provision inform consent participate study 8 . Active uncontrolled infection , include know history HIV/AIDS hepatitis B C. 9 . Any psychological , familial , sociological , geographical condition could potentially interfere compliance study protocol followup schedule . 10 . Patients receive anticoagulation therapy Coumadin eligible study . [ Patients noncoumadin anticoagulant ( Lovenox , Xarelto , etc . ) eligible study . Patients Coumadin transition lovenox prior start study treatment eligible ] . 11 . Patients prior history thromboembolic event within last 12 month treat systemic anticoagulation exclude . 12 . Patients allergic sesame seed oil cottonseed oil exclude . 13 . Major surgery ( eg , require general anesthesia ) within 3 week screen , fully recover prior surgery ( ie , unhealed wound ) . Note : subject plan surgical procedure conduct local anesthesia may participate .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Testosterone</keyword>
	<keyword>Enzalutamide</keyword>
	<keyword>Abiraterone</keyword>
	<keyword>Androgen Ablative Therapies</keyword>
	<keyword>Bipolar Androgen Therapy</keyword>
</DOC>